Dario Siniscalco Chem D PhD

Dario Siniscalco Chem D PhD

Research Associate for the Department of Experimental Medicine of the Second University of Naples (SUN) in Italy. He graduated in Chemistry from the University of Naples “Federico II” in 2000 and received his PhD in Pharmacological Sciences from SUN in 2004. He completed his neuropathology fellowship at University of Alabama at Birmingham in USA before joining the Second University of Naples staff in 2006.

He is a registered member of the following scientific societies: Order of the Chemists of Campania, National Council for Chemistry, Stem Cell Research Italy, European Association for Chemical and Molecular Sciences, Italian Pharmacological Society, Cell Death Research Group - University of Alabama at Birmingham in USA.

In 2010, in collaboration with Dr Nicola Antonucci, he founded a research group to study cellular and molecular changes in autism spectrum disorders. Author and co-author of 39 scientific peer-reviewed papers and 9 book chapters. Presented his work to 92 national and international conferences. He is serving as an editorial board member of reputed journals and reviewer of more than 25 journals.

His main research interests are gene expression and molecular regulation in autism spectrum disorders, the use of stem cells as therapeutic tool in autism, the role of macrophage activation in autism. Other research interests are stem cells therapy for the neuronal recovery and studying of neuronal apoptosis. Role of  bcl-2 family, caspases, and cell cycle regulator genes.

Effects of Gc-MAF in macrophages from autistic children

Autism spectrum disorders (ASDs) are heterogenous neurodevelopmental pathologies characterized by impairments in social interaction and communication and by restricted, repetitive, and stereotyped patterns of behaviour. Commonly, the symptoms are apparent before the age of 3. ASDs have been recognized as public health problem. Prevalence rate of ASDs is fast increasing. The lack of specific biologic markers for diagnosis provides challenges in monitoring the prevalence of ASDs. There are currently no approved treatments for ASD core symptoms. Pharmacological intervention does not affect all core symptoms, providing partial relief for some dysfunctional behaviour.
Gc protein-derived Macrophage Activating Factor (Gc-MAF) has shown interesting properties in decreasing autism symptoms, as well as in treating several human diseases.
Immune dysregulation and oxidative stress have been demonstrated in ASDs. Peripheral blood mononuclear cells (PBMCs) are strongly involved in these cellular mechanisms.
In this study, using molecular and cellular biology techniques, we investigated the activation of PBMC-derived macrophages in ASD children. The effects of Gc-MAF administration on our in vitro system were also studied.